ethylmethylhydroxypyridine-succinate and Chronic-Disease

Chronic cerebral ischemia (CCI) is a common cerebrovascular syndrome, the development of which is associated with a high risk of increasing cognitive, behavioral, and motor disorders, and the formation of a patient's dependence on others. Timely start of treatment can slow down the course of the disease, make it more favorable. The review considers the possibility of using the domestic neuroprotector mexidol in patients with CCI. The results of a series of clinical studies on the use of ethylmethylhydroxypyridine succinate (mexidol) in patients with CCI are analyzed. The effectiveness of the drug in relieving cognitive, affective and motor disorders is noted. Information about the good tolerance of mexidol is presented.. Хроническая ишемия головного мозга (ХИМ) — распространенный цереброваскулярный синдром, развитие которого ассоциировано с высоким риском нарастания когнитивных, поведенческих, моторных нарушений, формированием зависимости больного от посторонней помощи. Своевременное начало лечения способно замедлить течение заболевания, сделать его более благоприятным. В обзоре представлен анализ результатов клинических исследований, посвященных эффективности этилметилгидроксипиридина сукцината (Мексидола) у пациентов с ХИМ. Отмечена эффективность препарата при купировании когнитивных, аффективных и моторных нарушений. Приведены сведения о хорошей переносимости этилметилгидроксипиридина сукцината.

Topics: Antioxidants; Brain Ischemia; Chronic Disease; Humans; Picolines; Pyridines

The authors analyze their experience in the application of mexicor, a Russian cytoprotector, in 50patients with chronic coronary artery disease (CAD) and 51 patients with acute coronary syndrome. In additional to cytoprotective action, the use of mexidor in complex therapy of CAD lowers the functional activity of thrombocytes, eliminates high blood viscosity syndrome, and lowers low density lipoprotein cholesterol level. These favorable changes in hemorheological parameters improves myocardial perfusion, lowers the strength and frequency of coronary pain attacks, retards postinfarction left ventricular remodeling, and increases the quality of life of patients with various CAD forms.

Topics: Acute Disease; Adult; Angina, Unstable; Blood Platelets; Blood Viscosity; Chronic Disease; Coronary Artery Disease; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines